KORTUC key facts
as of Oct 2026- Developer of a novel radiosensitizer designed to enhance the efficacy of cancer radiotherapy.
- KORTUC is valued at approximately $281.4M as of Oct 2026 (last reported valuation).
- It has raised $44.4M; the latest was Later Stage VC ($20.0M) in Aug 2025.
- Notable investors include SBI Investment, Nissay Capital, Pegasus Tech Ventures, Loyal VC, AXA Japan — 11 tracked in total.
- KORTUC has filed 1 Form D with the SEC, most recently Nov 2023 ($3K sold to 1 investors).
- Status: Privately Held (backing).
KORTUC's last reported valuation, Nov 2021. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch KORTUC: the Monday email on marks, rounds and moves
KORTUC funding rounds
No funding rounds for KORTUC are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs KORTUC
11+KORTUC valuation
KORTUC's last reported valuation was $281 million in Nov 2021. No priced round, secondary trade or fund mark has surfaced since.
How much has KORTUC raised?
KORTUC has filed 1 Form D with the SEC, most recently in Nov 2023 ($2,783 sold to 1 investor).
KORTUC investors
11 investors are on record for KORTUC, including SBI Investment, Nissay Capital, Pegasus Tech Ventures and Loyal VC.
About KORTUC
Developer of a novel radiosensitizer designed to enhance the efficacy of cancer radiotherapy. The company develops hydrogen peroxide-based drugs delivered via a prefilled syringe, injected intratumorally before radiotherapy to make hypoxic tumors responsive to radiation by inactivating antioxidative enzymes, enabling medical professionals to control the radiated tumors and improve the efficacy of radiation therapy.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2015
- Employees
- 3
- Website
- kortuc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.